Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer: TEXT and SOFT Trials

- Regan, Meredith M., Francis, Prudence A., Pinotti, Graziella, Price, Karen N., Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D., Pagani, Olivia, Fleming, Gini F., Walley, Barbara A., Viale, Giuseppe, Colleoni, Marco, Láng, István, Gómez, Henry L., Tondini, Carlo

Acute radiation skin toxicity associated with BRAF inhibitors

- Pulvirenti, T., Hong, A., Long, G. V., Wang, W., Clements, A., Forstner, D., Suchowersky, A., Guminski, A., McNeil, C., Hersey, P., Fogarty, G., Kefford, R.

Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

- Francis, Prudence A., Fleming, Gini F., Burstein, Harold J., Davidson, Nancy E., Geyer, Charles E., Walley, Barbara A., Ingle, James N., Coleman, Robert E., Müller, Bettina, Le Du, Fanny, Loibl, Sibylle, Winer, Eric P., Láng, István, Ruepp, Barbara, Loi, S, Colleoni, M, Coates, AS, Gelber, RD, Goldhirsch, A, Regan, MM, SOFT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation),, Ciruelos, Eva M., Bonnefoi, Hervé R., Bellet, Meritxell, Bernardo, Antonio, Climent, Miguel A., Martino, Silvana, Bermejo, Begoña

Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials

- Pagani, Olivia, Walley, Barbara A., Stearns, Vered, Bonnefoi, Hervé R., Martino, Silvana, Geyer, Charles E., Chini, Claudio, Puglisi, Fabio, Spazzapan, Simon, Ruhstaller, Thomas, Winer, Eric P., Ruepp, Barbara, Fleming, Gini F., Loi, Sherene, Coates, AS, Gelber, RD, Goldhirsch, A, Regan, MM, Francis, Prudence A., SOFT and TEXT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation),, Colleoni, Marco, Láng, István, Gomez, Henry L., Tondini, Carlo, Burstein, Harold J., Goetz, Matthew P., Ciruelos, Eva M.

Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial

- Ribi, Karin, Luo, Weixiu, Parmar, Vani, Tondini, Carlo, Kerbrat, Pierre, Perelló, Antonia, Neven, Patrick, Torres, Roberto, Lombardi, Davide, Puglisi, Fabio, Karlsson, Per, Ruhstaller, Thomas, Bernhard, Jürg, Colleoni, Marco, Coates, Alan S., Goldhirsch, Aron, Price, Karen N., Gelber, Richard D., Regan, Merideth M., Fleming, Gini F., Francis, Prudence A., Burstein, Harold J., Ciruelos, Eva, Bellet, Meritxell, Pavesi, Lorenzo, Lluch, Ana, Visini, Marilena

Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

- Weber, Jeffrey S., Schadendorf, Dirk, Ascierto, Paolo A., Sandhu, Shahneen, Eigentler, Thomas, Gutzmer, Ralf, Hassel, Jessica C., Robert, Caroline, Carlino, Matteo S., Di Giacomo, Anna Maria, Butler, Marcus O., Muñoz-Couselo, Eva, Del Vecchio, Michele, Brown, Michael P., Rutkowski, P, Haydon, A, Grob, J-J, Schachter, J, Queirolo, P, de la Cruz-Merino, L, van der Westhuizen, Andre, Menzies, AM, Re, S, Larkin, James, Bas, T, de Pril, V, Braverman, J, Tenney, DJ, Tang, H, Long, GV, Atkinson, Victoria, Schenker, Michael, Pigozzo, Jacopo, Gogas, Helen, Dalle, Stéphane, Meyer, Nicolas

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 Study

- Colleoni, Marco, Giobbie-Hurder, Anita, Chirgwin, Jacquie, Pienkowski, Tadeusz, Wardley, Andrew, Price, Karen N., Gelber, Richard D., Coates, Alan S., Goldhirsch, Aron, Regan, Meredith M., Thürlimann, Beat, Mouridsen, Henning, Mauriac, Louis, Forbes, John F., Paridaens, Robert, Láng, István, Smith, Ian

Anastrozole-induced carpal tunnel syndrome: results from the international breast cancer intervention study II prevention trial

- Spagnolo, Francesco, Sestak, Ivana, Howell, Anthony, Forbes, John F., Cuzick, Jack

Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V

- Colleoni, Marco, Sun, Zhuoxin, Goldhirsch, Aron, Price, Karen N., Karlsson, Per, Forbes, John F., Thürlimann, Beat, Gianni, Lorenzo, Castiglione, Monica, Gelber, Richard D., Coates, Alan S.

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the oblimersen melanoma study group

- Bedikian, Agop Y., Millward, Michael, Kirkwood, John M., Haluska, Frank G., Pehamberger, Hubert, Conry, Robert, Gore, Martin, Trefzer, Uwe, Pavlick, Anna C., DeConti, Ronald, Hersh, Evan M., Hersey, Peter

Cancer Risks for PMS2-Associated Lynch Syndrome.

- Ten Broeke, Sanne W., van der Klift, Heleen M., Gallinger, Steven, Gomez Garcia, Encarna, Figueiredo, Jane C., Haile, Robert, Hampel, Heather L., Hopper, John L., Hoogerbrugge, Nicoline, von Knebel Doeberitz, Magnus, Le Marchand, Loic, Letteboer, Tom G. W., Tops, Carli M. J., Jenkins, MA, Lindblom, A, Lindor, NM, Mensenkamp, AR, Møller, P, Newcomb, PA, van Os, TAM, Pearlman, R, Pineda, M, Rahner, N, Aretz, Stefan, Redeker, EJW, Olderode-Berends, MJW, Rosty, C, Schackert, HK, Scott, Rodney, Senter, L, Spruijt, L, Steinke-Lange, V, Suerink, M, Thibodeau, S, Bernstein, Inge, Vos, YJ, Wagner, A, Winship, I, Hes, FJ, Vasen, HFA, Wijnen, JT, Nielsen, M, Win, AK, Buchanan, Daniel D., de la Chapelle, Albert, Capella, Gabriel, Clendenning, Mark, Engel, Christoph

Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer

- Stockler, Martin R., Harvey, Vernon J., Gainford, M. Corona, Fong, Akiko, Paksec, Lisa, Sourjina, Tatiana, Zannino, Diana, Gebski, Val, Simes, R. John, Forbes, John F., Coates, Alan S., Francis, Prudence A., Byrne, Michael J., Ackland, Stephen P., Fitzharris, Bernie, Van Hazel , Guy, Wilcken, Nicholas R. C., Grimison, Peter S., Nowak, Anna K.

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

- Tebbutt, Niall C., Wilson, Kate, Forgeson, Garry, Cunningham, David, Saunders, Mark P., Stockler, Martin R., Chua, Yujo, Zalcberg, John R., Simes, R. John, Price, Timothy J., Gebski, Val J., Cummins, Michelle M., Zannino, Dianna, van Hazel, Guy A., Robinson, Bridget, Broad, Adam, Ganju, Vinod, Ackland, Stephen P.

Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: Predictive value of centrally reviewed expression of estrogen and progesterone receptors - International Breast Cancer Study Group

- Viale, Giuseppe, Regan, Meredith M., Braye, Stephen, Grigolato, Piergiovanni, Rusca, Tiziana, Gelber, Richard D., Castiglione-Gertsch, Monica, Price, Karen N., Goldhirsch, Aron, Gusterson, Barry A., Coates, Alan S., Maiorano, Eugenio, Mastropasqua, Mauro G., Golouh, Rastko, Perin, Tiziana, Brown, Robert W., Kovacs, Aniko, Pillay, Komala, Ohlschlegel, Christian

Differential benefit of adjuvant docetaxel-based chemotherapy in patients with early breast cancer according to baseline body mass index

- Desmedt, Christine, Fornili, Marco, Sotiriou, Christos, Piccart, Martine, Biganzoli, Elia, Clatot, Florian, Demicheli, Romano, De Bortoli, Davido, Di Leo, Angelo, Viale, Giuseppe, de Azambuja, Evandro, Crown, John, Francis, Prudence A.

Discordance in perceived needs between patients and physicians in oncology practice: a nationwide survey in Korea

- Shin, Dong Wook, Kim, So Young, Cho, Juhee, Sanson-Fisher, Robert W., Guallar, Eliseo, Chai, Gyu Young, Kim, Hak-Soon, Park, Bo Ram, Park, Eun-Cheol, Park, Jong-Hyock

Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study

- Bliss, Judith M., Kilburn, Lucy S., van de Velde, Cornelius J. H., Lønning, Per. E., Morden, James, Reise, Justine, Cisar, Laura, Menschik, Thomas, Coombes, R. Charles, Coleman, Robert E., Forbes, John F., Coates, Alan S., Jones, Stephen E., Jassem, Jack, Delozier, Thierry, Andersen, Jørn, Paridaens, Robert

Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer

- D'Amico, Anthony V., Chen, Ming-Hui, Crook, Juanita, Armstrong, John G., Malone, Shawn, Steigler, Allison, Dunne, Mary, Kantoff, Phillip W., Denham, James W.

Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial

- Sestak, Ivana, Distler, Wolfgang, Forbes, John F., Dowsett, Mitch, Howell, Anthony, Cuzick, Jack

Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic: an international, multicenter, comparative cohort study

- Glasbey, James C., Nepogodiev, Dmitri, Simoes, Joana F. F., Omar, Omar, Li, Elizabeth, Venn, Mary L., Abou Chaar, Mohammad K., Capizzi, Vita, Chaudhry, Daoud, Desai, Anant, Edwards, Jonathan G., Evans, Jonathan P., Fiore, Marco, Videria, Jose Flavio, Ford, Samuel J., Ganly, Ian, Griffiths, Ewen A., Gujjuri, Rohan R., Kolias, Angelos G., Kaafarani, Haytham M. A., Pockney, Peter